PTC Therapeutics, Inc. (PTCT)
NASDAQ: PTCT · Real-Time Price · USD
73.80
-0.05 (-0.07%)
Jun 1, 2026, 4:00 PM EDT - Market closed
PTC Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 827.11 | 1,731 | 806.78 | 937.82 | 698.8 | 538.59 | |
Revenue Growth (YoY) | -53.34% | 114.51% | -13.97% | 34.20% | 29.75% | 41.45% |
Cost of Revenue | 62.18 | 47.01 | 57.4 | 65.49 | 44.68 | 32.33 |
Gross Profit | 764.93 | 1,684 | 749.38 | 872.34 | 654.12 | 506.27 |
Selling, General & Admin | 352.37 | 347.14 | 300.91 | 332.54 | 326 | 285.77 |
Depreciation & Amortization Expenses | 32.53 | 24.74 | 60.74 | 222.64 | 116.55 | 54.75 |
Research & Development | 447.15 | 455.25 | 534.48 | 666.56 | 651.5 | 540.68 |
Other Operating Expenses | -8.78 | -10.43 | 155.82 | 90.1 | 7.48 | -0.5 |
Total Operating Expenses | 823.26 | 816.71 | 1,052 | 1,312 | 1,102 | 880.71 |
Operating Income | -58.33 | 866.94 | -302.57 | -439.5 | -447.41 | -374.44 |
Interest Expense | -167.17 | -152.23 | -166.99 | -129.18 | -90.87 | -86.02 |
Other Non-Operating Income (Expense) | -10.17 | -18.09 | 106.44 | -127.43 | -49.21 | -57.88 |
Total Non-Operating Income (Expense) | -177.34 | -170.32 | -60.55 | -256.61 | -140.08 | -143.9 |
Pretax Income | -235.67 | 696.62 | -363.12 | -696.11 | -587.49 | -518.34 |
Provision for Income Taxes | -48.94 | 13.98 | 0.18 | -69.51 | -28.47 | 5.56 |
Net Income | -186.73 | 682.64 | -363.3 | -626.6 | -559.02 | -523.9 |
Net Income to Common | -186.73 | 682.64 | -363.3 | -626.6 | -559.02 | -523.9 |
Shares Outstanding (Basic) | 80 | 80 | 77 | 75 | 72 | 70 |
Shares Outstanding (Diluted) | 82 | 88 | 77 | 75 | 72 | 70 |
Shares Change (YoY) | 3.54% | 14.92% | 2.68% | 4.33% | 1.79% | 6.72% |
EPS (Basic) | -2.33 | 8.58 | -4.73 | -8.37 | -7.79 | -7.43 |
EPS (Diluted) | -2.33 | 7.78 | -4.73 | -8.37 | -7.79 | -7.43 |
Shares Outstanding | 82.88 | 81.47 | 77.7 | 75.71 | 73.1 | 70.83 |
Free Cash Flow | -226.28 | 702.34 | -114.19 | -186.86 | -388.67 | -279.55 |
Free Cash Flow Per Share | -2.76 | 7.95 | -1.49 | -2.50 | -5.42 | -3.97 |
Gross Margin | 92.48% | 97.28% | 92.89% | 93.02% | 93.61% | 94.00% |
Operating Margin | -7.05% | 50.09% | -37.50% | -46.86% | -64.03% | -69.52% |
Profit Margin | -22.58% | 39.44% | -45.03% | -66.81% | -80.00% | -97.27% |
FCF Margin | -27.36% | 40.58% | -14.15% | -19.92% | -55.62% | -51.90% |
EBITDA | -11.32 | 905.75 | -226.91 | -202.91 | -318.57 | -310.31 |
EBITDA Margin | -1.37% | 52.34% | -28.13% | -21.64% | -45.59% | -57.61% |
EBIT | -58.33 | 866.94 | -302.57 | -439.5 | -447.41 | -374.44 |
EBIT Margin | -7.05% | 50.09% | -37.50% | -46.86% | -64.03% | -69.52% |
Effective Tax Rate | 20.77% | 2.01% | -0.05% | 9.98% | 4.85% | -1.07% |